Carcinosarcoma of the ovary — also designated malignant mixed Müllerian tumor (MMMT) — is a defined histological subtype of ovarian cancer with its own clinical pathway distinct from the more common epithelial subtypes.
This protocol applies to patients with carcinosarcoma (malignant mixed Müllerian tumor, MMMT) of the ovary. The specific histological diagnosis shapes treatment selection and eligibility for certain management strategies.
Molecular profiling — particularly BRCA1/2 mutation testing — is clinically relevant in this setting. For patients with a confirmed mutation, targeted maintenance therapy following completion of primary treatment may be considered. The full protocol details the eligible agent class, applicable clinical criteria, and sequencing — the approach goes beyond what is summarised here.